Introduction
Epidermal growth factor (EGF) interacts with EGF receptor (EGFR), leading to the receptor dimerization, activation of its kinase activity and autophosphorylation of EGFR on tyrosine residues (Pawson, 1995) . In many tumors, overexpression of EGFR leads to constitutive activation of the receptor and has been shown to correlate with tumor proliferation, metastasis, resistance to chemotherapy, and hence, poor prognosis (Mendelsohn and Baselga, 2000) . That EGF can activate nuclear factor-kB (NF-kB) has been demonstrated (Obata et al., 1996; Habib et al., 1998; Sun and Carpenter, 1998; Biswas et al., 2000; Haussler et al., 2005) , the mechanism of its activation, however, remains elusive. Whether EGF induces NF-kB activation through a pathway similar to that of tumor-necrosis factor (TNF) was investigated in the present study. We found that EGF-induced NF-kB activation occurred without serine phosphorylation and ubiquitination of IkBa and, thus, is IkBa kinase (IKK)-independent. Unlike TNF activation, EGF-induced NF-kB activation requires EGFR tyrosine kinase-mediated tyrosine phosphorylation of IkBa at residue 42.
Results
The goal of this study was to investigate the mechanism by which EGF activates the NF-kB pathway. Because NF-kB activation by TNF is well understood, we used TNF as a control for most studies.
EGF activates DNA binding of NF-kB in a dose-and time-dependent manner To determine the effect of EGF on the activation of NF-kB, H1299 cells were treated with different concentrations of EGF for 120 min or TNF for 30 min. Both EGF and TNF induced NF-kB activation in a dosedependent manner ( Figure 1a) ; maximum activation with EGF occurred at 100 ng/ml. NF-kB was activated by both agents in a time-dependent manner ( Figure 1b) . TNF induced NF-kB activation within 15 min and activation continued for 60 min, whereas EGF-induced NF-kB activation started at 60 min, reached a maximum at 120 min and then decreased at 240 min. Thus, EGFinduced NF-kB activation was slower than that by TNF. The slower kinetics and difference in the optimum level of activation suggest that the mechanism of NF-kB activation by EGF may be different from that by TNF.
EGF-induced NF-kB activation correlates with
IkBa degradation TNF-induced NF-kB activation requires the degradation of IkBa (Aggarwal, 2004) . To determine whether EGF-induced NF-kB activation is also mediated through IkBa degradation, cells were treated with TNF or EGF for the indicated times, and the cytoplasmic protein was extracted and analysed for IkBa by western blot analysis. TNF induced IkBa degradation within 15 min after treatment, and IkBa was resynthesized at 60 min ( Figure 1c ). EGF induced IkBa degradation within 60 min after treatment, and IkBa was resynthesized at 240 min ( Figure 1c ).
Unlike TNF, EGF did not induce IkBa serine phosphorylation Western blot analysis using phospho-specific anti-IkBa antibody showed that TNF induced phosphorylation of IkBa, but EGF had no effect on the serine phosphorylation of IkBa (Figure 1d ). These data suggest that, unlike TNF, EGF-induced IkBa degradation is not due to serine phosphorylation. Pretreatment with proteasome inhibitor ALLN prevented degradation of IkBa in ALLN-treated cells (Figure 1d , middle panel).
Degradation of IkBa protein is required for NF-kB activation induced by EGF Our above results suggest that EGF induces the degradation of IkBa. Whether IkBa degradation is needed for activation of NF-kB induced by EGF was investigated using three different inhibitors. We used lactacystin, a specific proteasome inhibitor (Fenteany et al., 1995) ; N-acetyl-Leu-Leu-Methioninal, a specific calpain inhibitor (Han et al., 1999) , and ALLN, an inhibitor of both proteasome and calpain (Vinitsky et al., 1992) . Results in Figure 2a suggest that all three inhibitors suppressed the EGF-induced IkBa degradation in a time-dependent manner. This correlated with suppression of EGF-induced NF-kB activation ( Figures  2b and c) . These results thus suggest that IkBa degradation is critical for NF-kB activation.
EGF did not induce ubiquitination of IkBa
To examine whether EGF induces ubiquitination of phosphorylated IkBa before degradation, we treated H1299 cells with ALLN and then with either TNF or EGF. As shown in Figure 3a , a ladder of highmolecular-mass proteins appeared following stimulation with TNF in presence of ALLN, whereas EGF-treated cells even in the presence of ALLN did not show any such ladder. This result suggests that EGF does not induce IkBa ubiquitination.
EGF did not induce IkBa kinase activation
Because our results indicated that EGF-induced NF-kB activation is not mediated through serine 32/36 phosphorylation of IkBa, we next explored whether EGF can activate IKK. An in vitro immune complex kinase assay /ml) were treated with different concentrations of TNF for 30 min or EGF for 120 min. (b) Cells were treated with 0.1 nM TNF or 100 ng/ml EGF for the indicated times. After treatment, nuclear extracts were prepared and then assayed for NF-kB activation by EMSA. (c) Both TNF and EGF induce IkBa degradation. Cells were treated with 0.1 nM TNF or 100 ng/ml EGF for the indicated times and then cytoplasmic extracts were prepared and western blot analysis was performed with anti-IkBa antibody. (d) TNF induces IkBa phosphorylation at the Ser 32/36 position, but EGF does not. Cells were preincubated with 100 mg/ml proteasome inhibitor ALLN for 1 h and then treated with either 0.1 nM TNF for 15 min or 100 ng/ml EGF for 60 min. Cytoplasmic extracts were prepared and then western blot analysis was performed with phospho-specific anti-IkBa antibody. Figure 2 (a) Proteasome and calpain inhibitors suppress EGF-induced IkBa degradation. Cells were treated with 100 ng/ml EGF for the indicated time intervals or pretreated with 50 mM lactacystin for 2 h or 50 mM calpain inhibitor, N-acetyl-Leu-Leu-Methioninal, or 100 mg/ml ALLN for 1 h followed by induction with 100 ng/ml EGF. Cytoplasmic extracts were prepared and then western blot analysis was performed with anti-IkBa antibody. (b) Proteasome and calpain inhibitors block EGF-induced activation of NF-kB. Cells were pretreated with 50 mM lactacystin for 2 h (left panel) or 50 mM calpain inhibitor (right panel) for 1 h followed by induction with 100 ng/ml EGF for 120 min. Nuclear extracts were prepared and analysed for NF-kB activation by EMSA. (c) Cells were pretreated with 100 ng/ml EGF for the indicated times or 100 mg/ml ALLN for 1 h followed by induction with EGF. Nuclear extracts were prepared, and analysed for NF-kB activation by EMSA. Figure 3 (a) EGF does not induce ubiquitination of IkBa. Cells were treated with 100 mg/ml ALLN for 1 h at 371C, followed by induction of either 0.1 nM TNF for 15 min or 100 ng/ml EGF for 60 min. Cytoplasmic extracts were immunoprecipitated with an antiIkBa antibody and then western blot analysis was performed with an anti-ubiquitin antibody. (b) EGF failed to activate IkBa kinase (IKK) in H1299 cells. Cells (4 Â 10 6 /ml) were activated with 0.1 nM TNF or 100 ng/ml EGF for the indicated time intervals. Whole-cell extracts were prepared and immune complex kinase assay was performed. To examine the effect of EGF on the level of expression of IKK proteins, western blot analysis was performed using anti-IKK-a and anti-IKK-b antibodies. (c) TNF as well as EGF induce NF-kB-dependent reporter gene (SEAP) expression in a dose-dependent manner. A293 cells were transiently transfected with an NFkB-containing plasmid linked to the SEAP gene or IkBa dominant-negative plasmid and then incubated for 24 h. After 24 h in culture with indicated doses of TNF and EGF, cell supernatants were collected and assayed for SEAP activity as described in Materials and methods.
using GST-IkBa-(1-54) as the substrate showed that EGF did not activate IKK, whereas TNF activated IKK as early as 5 min after TNF treatment, although activation ceased soon afterwards ( Figure 3b ). These results suggest that EGF neither activated IKK nor had any effect on the serine phosphorylation of IkBa.
EGF activates NF-kB-dependent reporter gene expression in a dose-dependent manner DNA binding alone is not sufficient to demonstrate that EGF can activate NF-kB (Campbell et al., 2004) . Therefore, we examined whether EGF activates NFkB reporter gene expression. Results in Figure 3c indicate that EGF induced NF-kB-dependent reporter gene expression in A293 cells in a dose-dependent manner and DN-IkBa inhibited the reporter activity.
EGF induces expression of NF-kB-regulated gene products characteristic of TNF We also investigated the effect of EGF on the expression of NF-kB-regulated gene products involved in the survival, proliferation and metastasis of cancer cells.
As shown in Figures 4a and b , EGF like TNF-induced significant expression of NF-kB-regulated gene products, including XIAP, IAP-1, IAP-2, COX-2, MMP-9 and cyclin D1, in a time-dependent manner.
Evidence that EGF activates NF-kB through a Ras-, TRADD-, TRAF2-, NIK-and Akt-dependent, but IKKbindependent mechanism EGF induced NF-kB reporter activity, and transfection with DN-IkBa, DN-TRADD, DN-TRAF2, DN-NIK, DN-Akt, DN-Ras plasmids suppressed EGF-induced NF-kB reporter activity. Transfection with IKK-b dominant-mutant plasmid did not significantly affect EGF but abolished TNF-induced NF-kB reporter activity (Figure 4c ). These results suggest that EGFinduced NF-kB activation can occur independent of IKK activation but requires Ras, TRADD, TRAF2, NIK and Akt.
Whether EGF activates Akt in these cells was also examined. As shown in Figure 5a , EGF activated Akt in a time-dependent manner and this activation was similar to that of TNF. Constitutive activation of EGFR leads to ligand-independent activation of NF-kB Recently, mutations in the EGFR have been described, which cause gene amplification and constitutive activation of EGFR (Lynch et al., 2004) . For instance, nonsmall cell lung adenocarcinoma (NSCLC) cell lines, HCC827 and H32555, exhibit deletion of exon 19 and mutation L859R respectively, which leads to amplification of EGFR and constitutive activation of EGFR and Akt (Amann et al., 2005) . Whether these cells exhibit ligand-independent NF-kB activation was examined. Results in Figure 5b show that both cell lines displayed constitutive activation of NF-kB, and treatment with the ligand had no effect on the activation.
EGF induces tyrosine phosphorylation of IkBa protein
Previously, our laboratory and others have shown that certain agents can activate NF-kB through tyrosine phosphorylation that may or may not lead to the degradation of IkBa (Imbert et al., 1996; Singh et al., 1996; Mukhopadhyay et al., 2000; Digicaylioglu and Lipton, 2001; . Whether EGF induces the tyrosine phosphorylation of IkBa was investigated. EGF-treated whole-cell lysates were immunoprecipitated with anti-IkBa antibody, followed by western blotting with anti-phosphotyrosine antibody. As shown in Figure 6a , EGF induced tyrosine phosphorylation of IkBa but TNF did not. These results indicate that EGF activates protein tyrosine kinase, which can cause phosphorylation of IkBa. (a) EGF induces tyrosine phosphorylation of IkBa in H1299 cells. Cells were treated with 0.1 nM TNF or 100 ng/ml EGF for the indicated times. Whole-cell extracts were prepared and 500 mg of sample was incubated with IkBa antibody overnight. Immunocomplex was precipitated with protein A/G-agarose beads and then fractionated on 10% SDS-PAGE. Western blot analysis was performed using anti-phosphotyrosine antibody. (b) EGF induces phosphorylation of IkBa at tyrosine 42. Whole-cell extracts were prepared and 500 mg of sample was incubated with IkBa antibody overnight. Immunocomplex was precipitated with protein A/Gagarose beads and then fractionated on 10% SDS-PAGE. Western blot analysis was performed using anti-phospho-IkBa (Tyr-42) antibody. (c) Transfection with pCMV4-F IkBa/42F plasmid abolishes EGF-induced phosphorylation of IkBa. A293 cells were transiently transfected with pCMV4-F IkBa, pCMV4-F IkBa/42F plasmids by the Fugene method. After 24 h of incubation, cells were washed and incubated with complete medium containing 100 ng/ml of EGF for 24 h. Lysate containing 500 mg of proteins in extraction buffer was incubated with 1 mg/ml concentration of FLAG antibody overnight. Immunocomplex was precipitated using protein A/Gagarose beads for 1 h at 41C, fractionated on 10% SDS-PAGE gel and probed with phospho-IkBa (Tyr 42) antibody. Figure 7 (a) Dose-dependent inhibition of phospho-EGFR expression after treatment with AEE788. Cells were pretreated with indicated concentration of AEE788 for 2 h, followed by induction with 100 ng/ml EGF for 120 min. Whole-cell extracts were prepared and analysed for p-EGFR and EGFR expression by western blotting. (b) EGFR inhibitor AEE788 suppresses EGF-induced tyrosine phosphorylation of IkBa. Cells were preincubated with 20 mM AEE788 and/or 100 mg/ml ALLN for 1 h and then treated with 0.1 nM TNF for 30 min or 100 ng/ml EGF for 120 min. Whole-cell extracts were prepared, and 500 mg of sample was incubated with anti-IkBa antibody overnight. Immunocomplex was precipitated with protein A/G-agarose beads and western blot analysis was performed using anti-phosphotyrosine antibody. (c) EGFR inhibitor AEE788 suppresses EGF but not TNF-induced activation of NF-kB. Cells were preincubated with indicated concentrations of AEE788 for 1 h and then treated with 0.1 nM TNF for 30 min or 100 ng/ml EGF for 120 min. After these treatments, nuclear extracts were prepared and then assayed for NF-kB activation by EMSA. (d) EGFR inhibitor AEE788 suppresses EGF but not TNF-induced NF-kB-dependent reporter gene expression. Briefly, A293 cells were transiently transfected with an NF-kB-containing plasmid linked to the SEAP gene and then incubated for 24 h. After incubation, cells were treated with 10 mM AEE788 for 1 h and then stimulated with 1 nM TNF or 100 ng/ml EGF for 24 h. Thereafter, the supernatants were collected and assayed for SEAP activity. (e) A schematic diagram of EGF and TNF-induced NF-kB activation. IkBa kinase kinase (IKKK) involved may be Akt or other hypothetical kinases.
EGF induces phosphorylation of IkBa at tyrosine 42 EGF induced phosphorylation of IkBa, which is recognized by the antibody against the tyrosine residue 42. These results suggest that EGF induces phosphorylation of IkBa at tyrosine 42 (Figure 6b ).
To confirm further that EGF induces phosphorylation of IkBa at tyrosine 42, we transfected the 293 cells with a FLAG-tagged wild-type IkBa plasmid and mutant IkBa plasmid in which tyrosine 42 has been mutated to phenylalanine (Y42F); and then cells were treated with EGF. Whole-cell lysates were immunoprecipitated with anti-FLAG antibodies followed by western blot using the anti-phospho-IkBa (Tyr 42). As shown in Figure 6c , EGF induced tyrosine phosphorylation of IkBa in cells transfected with wild-type plasmid but not in cells transfected with mutant (Y42F) IkBa plasmid. These results confirm that EGF induces phosphorylation of IkBa at tyrosine 42.
EGFR kinase inhibitor suppresses EGF-induced tyrosine phosphorylation of IkBa
It is possible that tyrosine phosphorylation of IkBa is induced by activation of EGFR tyrosine kinase. AEE788 has been shown to be a specific inhibitor of EGFR tyrosine kinase (Traxler et al., 2004) . Whether AEE788 can suppress EGFR phosphorylation in H1299 cells was investigated. We found that EGF induced phosphorylation of its receptor whereas AEE788 suppressed this phosphorylation in a dose-dependent manner (Figure 7a ).
Whether pretreatment of cells with AEE788 can suppress tyrosine phosphorylation of IkBa was also examined. As shown in Figure 7b , EGF induced tyrosine phosphorylation of IkBa whereas AEE788 suppressed the phosphorylation.
EGFR inhibitor suppresses EGF-induced NF-kB activation
Whether AEE788 also inhibits EGF-induced NF-kB activation was examined. As shown in Figure 7c , EGFinduced NF-kB activation was inhibited on treatment with AEE788. However, AEE7888 had no effect on TNF-induced NF-kB activation. We also investigated the effect of AE7888 on EGF-induced NF-kB-mediated transcriptional activity. As shown in Figure 7d , EGF induced transcription of the reporter gene was suppressed by AEE788 in a dose-dependent manner.
Discussion
We present evidence that EGF can activate NF-kB and NF-kB-regulated gene expression like TNF, but through a different pathway (Figure 7e ). Our results demonstrate for the first time that EGF-induced NF-kB activation requires tyrosine phosphorylation of IkBa. The current study suggests that EGF-induced IkBa phosphorylation is induced by the EGFR tyrosine kinase. Whether EGFR directly phosphorylates IkBa or indirectly is not clear.
We also show for the first time that IkBa is tyrosine phosphorylated at 42 on treatment with EGF as shown previously for pervanadate (Imbert et al., 1996; Mukhopadhyay et al., 2000) . We also found that transfection of cells with an IkBa plasmid in which tyrosine 42 has been mutated to phenylalanine, abolished the EGF-induced phosphorylation of IkBa. Tyrosine phosphorylation of IkBa can regulate NF-kB activation both positively as in case of EGF, PV , or H 2 O 2 or negatively as in case of TNF (Singh et al., 1996) . Our results differ from Haussler et al. (2005) , who showed that EGF-induced NF-kB activation requires phosphorylation of serine residue in human proximal tubule cells. Whether the difference in their report and ours is due to the cell types used, is not clear.
We found that EGF-induced tyrosine phosphorylation of IkBa lead to its degradation. These results are consistent with that reported previously for pervanadate by our group . IkBa degradation was critical for EGF-induced NF-kB activation as treatment of cells with ALLN, lactacystin or calpain inhibitor, suppressed both IkBa degradation and NF-kB activation. We also found that while TNF induces ubiquitination of IkBa, EGF does not. IkBa is known to undergo degradation through not only Ubmediated modifications but also non-Ub-mediated process. For instance, calpain has been shown to induce the degradation of IkBa through the Ub-independent pathway (Han et al., 1999) . Thus, these findings indicate that the mechanism of EGF-induced IkBa degradation is different from that of TNF.
We also found that EGF-activated Akt and DN-Akt suppressed EGF-induced NF-kB-mediated gene transcription. Our results are in agreement with Biswas et al. (2000) , who showed that EGF-induced NF-kB-activation can be blocked by inhibition of PI3-kinase. Our finding that DN-Ras blocked EGF-induced NF-kB activation is in agreement with the observations that EGF is known to activate Ras (van der Geer et al., 1994) and activated Ras can induce NF-kB reporter activity (Finco and Baldwin, 1993) . It is also in agreement with a recent report from our laboratory that Ras farnesylation inhibitors are potent blockers of NF-kB activation by a variety of agents (Takada et al., 2004b) .
We also present evidence that TRADD, TRAF2 and NIK are involved in EGF-induced NF-kB activation. The involvement of NIK is in agreement with a report by Habib et al. (1998) . Our study is the first, however, to demonstrate the role of TRADD and TRAF2 in EGFinduced NF-kB activation. TRAF2 is known to bind to NIK (Malinin et al., 1997) . Thus, it is possible that EGFR binds to TRADD-TRAF2 and NIK, leading to NF-kB activation. We also found that EGF-induced NF-kB activation is IKK-independent, as indicated by the lack of phosphorylation of IkBa at serine, lack of IKK activation and lack of effect of DN-IKK on NFkB-reporter activity. Our observation, however, differs from that of Biswas et al. (2000) , who showed that DN-IKK blocks EGF-induced NF-kB activation. It is possible that the difference in their report and ours is due to the cell types used. Also, Biswas et al. (2000) did not investigate all the steps of NF-kB activation systematically, as reported here. If EGF can induce tyrosine phosphorylation of IkBa, leading to NF-kB activation, the modulation of EGFR activation by TRADD, TRAF2 and NIK is not clear. EGFR has been shown to form a complex with RIP, another adaptor protein required for NF-kB activation induced by TNF (Hsu et al., 1996) and EGF (Habib et al., 1998) . Since RIP is known to bind TRADD and TRAF2, it is possible that TRADD, TRAF2, NIK and RIP form a complex with EGFR, thus leading to NF-kB activation. Alternatively, the possibility that this complex may recruit a yet unidentified tyrosine kinase that phosphorylates IkBa cannot be ruled out.
We also found that EGF induced the expression of gene products involved in proliferation (cyclin D1 and COX-2), invasion (MMP-9) and the suppression of apoptosis (XIAP, IAP-1 and IAP-2). EGF-induced NFkB activation has also been implicated in cyclin D1-dependent cell cycle progression (Biswas et al., 2000) .
Using two different NSCLC cell lines, H3255 and HCC827, which exhibit L858R mutation and exon 19 deletion respectively (Tracy et al., 2004) , we show that both cell lines exhibit ligand-independent NF-kB activation. These results suggest the potential of EGFR inhibitors in suppressing the growth of NSCLC cells with EGFR-activating mutations through the suppression of ligand-independent NF-kB activation. Thus, overall our study suggests that EGF activates NF-kB through a mechanism that differs from that of TNF and that EGFR-mediated NF-kB activation may play a critical role in tumorigenesis.
Materials and methods

Reagents
Most of the reagents employed in the studies were as described in . EGF was obtained from Sigma Chemical Company (St Louis, MO, USA). AEE 788 was kindly provided by Novartis Pharmaceuticals. Anti-phospho EGFR (Tyr 1068) and EGFR antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA). Anti-phospho-IkBa (Tyr-42) antibody was purchased from ECM Biosciences (Versailles, KY, USA). Electrophoretic mobility shift assay Electrophoretic mobility shift assay (EMSA) was performed as described previously (Chaturvedi et al., 2000) .
Cell lines
Western blot analysis
Western blot analysis was performed as described previously .
IKK assay IKK assay was performed using a method described previously .
NF-kB-dependent reporter gene expression assay Reporter gene expression assay was performed as described previously (Takada et al., 2004a) .
Identification of tyrosine-phosphorylated IkBa
Immunoprecipitation assay for identification of tyrosinephosphorylated IkBa was performed as described previously .
Transient transfection with IkBa gene
Briefly, the FLAG-tagged IkBa gene cloned into the eukaryotic expression vector pCMV4 (pCMV4-F IkBa, pCMV4-F IkBa/42F) were transiently transfected into 50% confluent A293 cells by the Fugene6 method (Roche Molecular Biochemicals, Mannheim, Germany).
Abbreviations
EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; EMSA, electrophoretic mobility shift assay; IkB, inhibitory subunit of NF-kB; NF-kB, nuclear factor-kB.
